1) Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine. CLIN INFECT DIS 2012; 54:17-24. (IF=9.15).

2) Safe pseudovirus-based assay for neutralization antibodies against influenza A(H7N9) virus. EMERG INFECT DIS 2013; 19:1685-7. (IF=6.994) 

3) Kinetics of serological responses in influenza A(H7N9)-infected patients correlate with clinical outcome in China, 2013. Euro Surveill 2013; 18:20657. (IF=5.983)

4) Sequential immunization with consensus influenza hemagglutinins raises cross-reactive neutralizing antibodies against various heterologous HA strains. VACCINE 2017 2017-01-05;35(2):305-12.

5) Induction of Broadly Cross-Reactive Stalk-Specific Antibody Responses to Influenza Group 1 and Group 2 Hemagglutinins by Natural H7N9 Virus Infection in Humans. J INFECT DIS 2017 2017-02-15;215(4):518-28. (IF=6.344)

6) 表达甲型H1N1流感病毒血凝素抗原的DNA疫苗构建及其免疫原性评价.国际生物制品学杂志.34(03): 121-125. 2011.